Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV Risk Reduction and Drug Abuse Treatment in Iran
NCT00398008Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Oct 2004
- Primary completion
- Dec 2006
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) and human immunodeficiency virus infection (HIV) comparing DC-HIV plus buprenorphine maintenance with DC-HIV plus naltrexone maintenance (2 arms). Primary endpoints: Time to resumption of heroin use at 26 weeks, Time to relapse at 26 weeks and 2 more. Planned start Oct 2004; status: withdrawn.
02
Drugs
buprenorphinenaltrexone
03
Conditions
opioid use disorder (OUD)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00398008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398008.